Soleno Therapeutics (SLNO) SVP reports RSU-related share withholding

Rhea-AI Filing Summary

Soleno Therapeutics senior vice president of clinical development reported a routine share withholding transaction related to equity compensation. On December 15, 2025, the officer had 812 shares of common stock withheld by the company at a price of $49.95 per share to cover tax obligations arising from the vesting and settlement of restricted stock units (RSUs). After this tax withholding, the officer beneficially owned 36,005 shares of Soleno Therapeutics common stock. Some of these holdings consist of RSUs, each representing a contingent right to receive one share of common stock, subject to vesting schedules and conditions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Huang Michael F.

Role Sr. VP of Clinical Development

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	812	$49.95	$41K

Holdings After Transaction: Common Stock — 36,005 shares (Direct)

Footnotes (1)

1. Represents shares that have been withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs") which vested on December 15, 2025. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huang Michael F.

(Last) (First) (Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP of Clinical Development

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		F(1)		812	D	$49.95	36,005(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs") which vested on December 15, 2025.

2. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

	/s/ Anish Bhatnagar, Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Soleno Therapeutics (SLNO) report in this Form 4?

The filing reports that a senior vice president of clinical development had 812 shares of common stock withheld on December 15, 2025 to satisfy tax withholding obligations tied to vesting restricted stock units.

How many Soleno Therapeutics (SLNO) shares does the reporting person own after the transaction?

Following the reported tax withholding, the officer beneficially owns 36,005 shares of Soleno Therapeutics common stock.

What is the role of the insider involved in this Soleno Therapeutics (SLNO) Form 4 filing?

The reporting person is an officer of Soleno Therapeutics, serving as Senior Vice President of Clinical Development.

What was the price used for the Soleno Therapeutics (SLNO) share withholding?

The company withheld 812 shares of common stock at a price of $49.95 per share to cover the officer's tax withholding obligations on RSU settlement.

How are RSUs described in this Soleno Therapeutics (SLNO) insider filing?

The filing states that certain securities are restricted stock units (RSUs), and that each RSU represents a contingent right to receive one share of common stock, subject to an applicable vesting schedule and conditions.

Why were Soleno Therapeutics (SLNO) shares withheld from the reporting person?

The shares were withheld by Soleno Therapeutics to satisfy the reporting person's tax withholding obligations arising from RSUs that vested on December 15, 2025.